ClinicalTrials.gg
CompletedNCT04956575Updated Oct 27, 2023Results posted

A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults

A Phase 1/2 interventional study of mRNA-1010 and Placebo in Seasonal Influenza, sponsored by ModernaTX, Inc.. Completed at 21 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-27.

Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 1/2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
885
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human — 2 open to participants now, 2 under way, none of them phase 3. mRNA-1010 influenza vaccine · Influenza, Human.

Enrollment
5th of 12
885 · median 471
Started
2021
the only one that year
Phase 1/2
2 of 12
none open now
Registered
1st of 12
by date
Lead sponsor
12 of 12
ModernaTX, Inc.

Among the 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human, this one is the 5th largest by enrollment, is the only one that started in 2021, is one of 2 in phase 1/2, and was the 1st registered.

Influenza, Human

2,360 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

2 of the 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About mRNA-1010 influenza vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 123 Influenza, Human studies recruiting now, 66 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 68 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human, or all of them as a file.
02

Study summary

The study comprises 3 parts: Phase 1/2, Phase 2 Northern Hemisphere (NH), and Phase 2 extension. The primary objective of this study is to evaluate the safety, reactogenicity, and humoral immunogenicity of mRNA-1010 vaccine.

03

Conditions studied

  • Seasonal Influenza

Browse trials for

Keywords

  • Influenza vaccine
  • mRNA-1010
  • Moderna
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

Phase 1/2:

  • Participant has a (BMI) of 18 kilograms (kg)/square meter (m\^2) to 35 kg/m\^2 (inclusive) at the Screening Visit.
  • Participant is in good health, in the opinion of the Investigator, based on review of medical history and physical examination performed at screening.
  • For female participants of : negative pregnancy test, adequate or has abstained from all activities that could result in pregnancy for at least 28 days prior to Day 1, agreement to continue adequate contraception through 3 months following vaccine administration, and not currently breastfeeding.

Phase 2 NH and Phase 2 Extension:

  • Participant is medically stable, in the opinion of the Investigator, based on review of medical history and physical examination performed at screening.
  • For female participants of childbearing potential: negative pregnancy test, adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to Day 1, agreement to continue adequate contraception through 3 months following vaccine administration, and not currently breastfeeding.

Key Exclusion Criteria:

Phase 1/2:

  • Participant has had significant exposure to someone with laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, COVID-19, or influenza-like illness (ILI) in the past 14 days prior to the Screening Visit, as defined by the United States Centers for Disease Control and Prevention (CDC) as close contact with someone who has COVID-19.
  • Participant has a positive SARS-CoV-2 reverse transcriptase polymerase chain reaction (RT-PCR) or antigen test in the past 10 days prior to the Screening Visit.
  • Participant is acutely ill or febrile (body temperature ≥ 38.0 degrees Celsius [°C]/100.4 degrees Fahrenheit [°F]) 72 hours prior to or at the Screening Visit or Day 1.
  • Participant has a pre-existing medical condition that is not stable, at the discretion of the Investigator.
  • Participant has a medical, psychiatric, or occupational condition that may pose additional risk as a result of participation or that could interfere with safety assessments or interpretation of results according to the Investigator's judgment.
  • Participant has received systemic or immune-modifying drugs for >14 days in total within 6 months prior to Screening Visit (for ≥10 milligrams [mg]/day of prednisone equivalent) or is anticipating the need for immunosuppressive treatment at any time during participation in the study.
  • Participant has received or plans to receive any licensed vaccine ≤28 days prior to the product (IP) injection (Day 1) or plans to receive a licensed vaccine within 28 days after the IP injection, with the exception of vaccines authorized or approved for the prevention of COVID-19 (regardless of type of vaccine) that become available to participants during the study. Efforts should be made to space study vaccination and COVID-19 vaccination by at least 7 and preferably 14 days, but COVID-19 vaccination should not be delayed.
  • Participant has received a seasonal influenza vaccine or any other investigational influenza vaccine after 01 January 2021.

Phase 2 NH:

  • Participant has had close contact to someone with SARS-CoV-2 infection or COVID-19 as defined by the CDC (CDC 2021a) in the past 14 days prior to the Screening Visit, unless the participant has been fully vaccinated for COVID-19.
  • Participant is acutely ill or febrile (body temperature ≥ 38.0°C/100.4°F) 72 hours prior to or at the Screening Visit or Day 1. Participants meeting this criterion may be rescheduled within the 28-day screening window and will retain their initially assigned participant number.
  • Participant has a medical, psychiatric, occupational condition, or history of substance abuse that may pose additional risk as a result of participation or that could interfere with safety assessments or interpretation of results according to the Investigator's judgment.
  • Participant has a current or previous diagnosis of immunocompromising/immunosuppressive condition, immune mediated disease requiring immune-modifying therapy, asplenia, recurrent severe infections ( [HIV] positive participants on antiretroviral therapy with cluster of differentiation [CD] 4 count ≥ 350 cells/mm3 and HIV RNA ≤ 500 copies/mL within the past 12 months are permitted).
  • Participant has received systemic immunosuppressants or immune-modifying drugs for > 14 days in total within 6 months prior to Screening Visit (for corticosteroids ≥ 10 mg/day of prednisone or equivalent) or is anticipating the need for systemic immunosuppressive treatment at any time during participation in the study.
  • Participant has a history of anaphylaxis, urticaria, or other significant AR requiring medical intervention after receipt of a vaccine or any of the components contained in the mRNA 1010 or the comparator vaccine, which is an egg-based influenza vaccine.
  • Participant has received or plans to receive any licensed vaccine ≤ 28 days prior to the IP injection (Day 1) or plans to receive a licensed vaccine within 28 days after the IP injection, with the exception of vaccines authorized or approved for the prevention of COVID-19 (regardless of type of vaccine) that become available to participants during the study. Efforts should be made to space study vaccination and COVID-19 vaccination by at least 7 and preferably 14 days, but COVID-19 vaccination should not be delayed.
  • Participant has received a seasonal influenza vaccine or any other investigational influenza vaccine within 6 months prior to the Screening Visit.
  • Participant has tested positive for influenza by CDC-recommended testing methods within 6 months prior to the Screening Visit.
  • Participant has participated in an interventional clinical study within 28 days prior to the Screening Visit based on the medical history interview or plans to do so while participating in this study.

Phase 2 Extension:

  • Participant has had close contact to someone with SARS-CoV-2 infection or COVID-19 as defined by the CDC in the past 10 days prior to the Screening Visit.
  • Participant is acutely ill or febrile (body temperature ≥ 38.0°C/100.4°F) 72 hours prior to or at the Screening Visit or Day 1. Participants meeting this criterion may be rescheduled within the 28-day screening window and will retain their initially assigned participant number.
  • Participant has a medical, psychiatric, occupational condition, or history of substance abuse that may pose additional risk as a result of participation or that could interfere with safety assessments or interpretation of results according to the Investigator's judgment.
  • Participant has a current or previous diagnosis of immunocompromising/immunosuppressive condition, immune-mediated disease requiring immune-modifying therapy, asplenia, recurrent severe infections (HIV-positive participants on antiretroviral therapy with CD 4 count ≥ 350 cells/mm\^3 and HIV-RNA ≤ 500 copies/mL within the past 365 days are permitted).
  • Participant has received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 180 days prior to Screening Visit (for corticosteroids ≥ 10 mg/day of prednisone or equivalent) or is anticipating the need for systemic immunosuppressive treatment at any time during participation in the study.
  • Participant has a history of anaphylaxis, urticaria, or other significant AR requiring medical intervention after receipt of a vaccine or any of the components contained in the mRNA-1010 or the comparator vaccine, which is an egg-based influenza vaccine.
  • Participant has received or plans to receive any licensed vaccine ≤ 28 days prior to the IP injection (Day 1) or plans to receive a licensed vaccine within 28 days after the IP injection, with the exception of vaccines authorized or approved for the prevention of COVID-19 (regardless of type of vaccine) that become available to participants during the study. Efforts should be made to space study vaccination and COVID-19 vaccination by at least 7 and preferably 14 days, but COVID-19 vaccination should not be delayed.
  • Participant has received a seasonal influenza vaccine or any other investigational influenza vaccine within 180 days prior to the randomization visit.
  • Participant had tested positive for influenza by CDC-recommended testing methods within 180 days prior to the Screening Visit.
  • Participant has participated in an interventional clinical study within 28 days prior to the Screening Visit based on the medical history interview or plans to do so while participating in this study.

Other inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
885 participants (actual)

Study arms

  • Experimental
    Phase 1/2: mRNA-1010 Dose Level A

    Participants will receive mRNA-1010 at dose level A by intramuscular (IM) injection on Day 1.

    Biological: mRNA-1010

  • Experimental
    Phase 1/2: mRNA-1010 Dose Level B

    Participants will receive mRNA-1010 at dose level B by IM injection on Day 1.

    Biological: mRNA-1010

  • Experimental
    Phase 1/2: mRNA-1010 Dose Level C

    Participants will receive mRNA-1010 at dose level C by IM injection on Day 1.

    Biological: mRNA-1010

  • Experimental
    Phase 1/2: Placebo

    Participants will receive placebo matching to mRNA-1010 by IM injection on Day 1.

    Biological: Placebo

  • Active comparator
    Phase 2 NH: Active Comparator Dose Level A

    Participants will receive active comparator at dose level A by IM injection on Day 1.

    Biological: Active Comparator

  • Experimental
    Phase 2 NH: mRNA-1010 Dose Level D

    Participants will receive mRNA-1010 at dose level D by IM injection on Day 1.

    Biological: mRNA-1010

  • Experimental
    Phase 2 NH: mRNA-1010 Dose Level A

    Participants will receive mRNA-1010 at dose level A by IM injection on Day 1.

    Biological: mRNA-1010

  • Experimental
    Phase 2 NH: mRNA-1010 Dose Level B

    Participants will receive mRNA-1010 at dose level B by IM injection on Day 1.

    Biological: mRNA-1010

  • Active comparator
    Phase 2 Extension: Active Comparator Dose Level A

    Participants will receive active comparator at dose level A by IM injection on Day 1.

    Biological: Active Comparator

  • Experimental
    Phase 2 Extension: mRNA-1010 Dose Level D

    Participants will receive mRNA-1010 at dose level D by IM injection on Day 1.

    Biological: mRNA-1010

  • Experimental
    Phase 2 Extension: mRNA-1010 Dose Level E

    Participants will receive mRNA-1010 at dose level E by IM injection on Day 1.

    Biological: mRNA-1010

  • Experimental
    Phase 2 Extension: mRNA-1010 Dose Level F

    Participants will receive mRNA-1010 at dose level F by IM injection on Day 1.

    Biological: mRNA-1010

Interventions

  • BiologicalmRNA-1010

    Sterile liquid for injection

    Also known as: Seasonal influenza vaccine

  • BiologicalPlacebo

    0.9% sodium chloride solution for injection

  • BiologicalActive Comparator

    0.5 milliliter (mL) intramuscular (IM) injection

    Also known as: Licensed quadrivalent seasonal influenza

06

What researchers measure

Primary outcomes

  1. Number of Participants With Solicited Local and Systemic ARs

    Solicited ARs (local and systemic) were collected in the electronic diary (eDiary). Local ARs included: pain at injection site, erythema (redness) at injection site, swelling/induration (hardness) at injection site, and localized axillary swelling or tenderness ipsilateral to the injection arm. Systemic ARs included: headache, fatigue, myalgia (muscle aches all over the body), arthralgia (aching in several joints), nausea/vomiting, rash, body temperature (potentially fever), and chills. Solicited ARs (local and systemic) considered causally related to injection were graded 0-4; lower score indicates lower severity and a higher score indicates greater severity. Note, not all solicited ARs were considered adverse events (AEs). The Investigator reviewed whether the solicited AR was also to be recorded as an AE. Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is in Reported "Adverse Events" section and presented by Phase/dose group.

    Time frame: 7 days after vaccination

  2. Number of Participants With Unsolicited AEs

    An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. A treatment-emergent AE (TEAE) was defined as any event not present before exposure to vaccine or any event already present that worsens in intensity or frequency after exposure. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsens from baseline and is considered clinically significant in the medical and scientific judgment of the Investigator. A summary of SAEs and all nonserious AEs ("Other") reported up to the end of the study, regardless of causality, is located in the Reported "Adverse Events" section and presented by each Phase and dose group separately.

    Time frame: Up to 28 days after vaccination

  3. Number of Participants With SAEs, AEs of Special Interest (AESIs), Medically Attended AEs (MAAEs)

    An SAE was defined as any AE that resulted in death, is life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability/permanent damage, was a congenital anomaly/birth defect, or was an important medical event. AESIs included thrombocytopenia, new onset of or worsening of the protocol specified neurologic diseases, anaphylaxis, and myocarditis/pericarditis. An MAAE is an AE that leads to an unscheduled visit to an healthcare practitioner. This would include visits to a study site for unscheduled assessments (for example, abnormal laboratory follow-up, and/or COVID-19 and visits to healthcare practitioners external to the study site (for example, urgent care, primary care physician). A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section and presented by each Phase and dose group separately.

    Time frame: Up to 6 months (end of study)

  4. Phase 1/2: Geometric Mean Titer (GMT) of Anti-Hemagglutinin (HA) Antibodies at Day 29, as Measured by Hemagglutination Inhibition (HAI) Assay for Vaccine-Matched Seasonal Influenza A and B Strains

    Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. GMT 95% confidence interval (CI) was calculated based on the t-distribution of the log-transformed values then back transformed to the original scale for presentation.

    Time frame: Day 29

  5. Phase 2 NH: GMT of HA Antibodies at Day 29, as Measured by HAI Assay for Vaccine-Matched Seasonal Influenza A and B Strains

    Humoral immunogenicity relative to that of the active comparator (afluria quadrivalent) was assessed against vaccine-matched Influenza A and B strains at Day 29. Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. GMT 95% CI was calculated based on the t-distribution of the log-transformed values then back transformed to the original scale for presentation.

    Time frame: Day 29

  6. Phase 2 Extension: GMT of HA Antibodies at Day 29, as Measured by HAI Assay for Vaccine-Matched Seasonal Influenza A and B Strains

    Humoral immunogenicity relative to that of the active comparator (afluria quadrivalent) was assessed against vaccine-matched Influenza A and B strains at Day 29. Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. GMT 95% CI was calculated based on the t-distribution of the log-transformed values then back transformed to the original scale for presentation.

    Time frame: Day 29

  7. Phase 1/2: Percentage of Participants With Seroconversion, as Measured by HAI Assay for Vaccine-Matched Seasonal Influenza A and B

    Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. Seroconversion at a participant level was defined as (a) if lower limit of quantification (LLOQ) was 1:10, a post-baseline titer ≥1:40 if baseline was \<1:10 or a 4-fold or greater rise from baseline if baseline was ≥1:10 in anti-HA antibodies; or (b) if LLOQ was \>1:10, a post-baseline titer ≥4 x LLOQ if baseline was \<LLOQ, or 4-fold or greater increase from baseline if baseline was ≥LLOQ in anti-HA antibodies.

    Time frame: Day 29

  8. Phase 1/2: Geometric Mean Fold-Rise (GMFR) of Anti-HA Antibodies at Day 29, as Measured by HAI Assay for Vaccine-Matched Seasonal Influenza A and B Strains

    The GMFR measures the changes in immunogenicity titers or levels from Baseline within participants. Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. 95% CI was calculated based on the difference in the log-transformed values for GMFR, then back transformed to the original scale for presentation.

    Time frame: Day 1 (Baseline), Day 29

  9. Phase 2 NH: Percentage of Participants With Seroconversion, as Measured by HAI Assay for Vaccine-Matched Seasonal Influenza A and B

    Humoral immunogenicity relative to that of the active comparator (afluria quadrivalent) was assessed against vaccine-matched Influenza A and B strains at Day 29. Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. Seroconversion at a participant level was defined as (a) if LLOQ was 1:10, a post-baseline titer ≥1:40 if baseline was \<1:10 or a 4-fold or greater rise from baseline if baseline was ≥1:10 in anti-HA antibodies; or (b) if LLOQ was \>1:10, a post-baseline titer ≥4 x LLOQ if baseline was \<LLOQ, or 4-fold or greater increase from baseline if baseline was ≥LLOQ in anti-HA antibodies. 95% CI was calculated using the Clopper-Pearson method

    Time frame: Day 29

  10. Phase 2 Extension: Percentage of Participants With Seroconversion, as Measured by HAI Assay for Vaccine-Matched Seasonal Influenza A and B

    Humoral immunogenicity relative to that of the active comparator (afluria quadrivalent) was assessed against vaccine-matched Influenza A and B strains at Day 29. Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. Seroconversion at a participant level was defined as (a) if LLOQ was 1:10, a post-baseline titer ≥1:40 if baseline was \<1:10 or a 4-fold or greater rise from baseline if baseline was ≥1:10 in anti-HA antibodies; or (b) if LLOQ was \>1:10, a post-baseline titer ≥4 x LLOQ if baseline was \<LLOQ, or 4-fold or greater increase from baseline if baseline was ≥LLOQ in anti-HA antibodies. 95% CI was calculated using the Clopper-Pearson method

    Time frame: Day 29

Secondary outcomes

  1. Phase 1/2: GMT of Anti-HA Antibodies at Days 1, 8 and 181, as Measured by HAI Assay for Vaccine-Matched Seasonal Influenza A and B Strains

    Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. GMT 95% CI was calculated based on the t-distribution of the log-transformed values then back transformed to the original scale for presentation.

    Time frame: Day 1 (Baseline), Day 8 and Day 181

  2. Phase 1/2: GMFR of Anti-HA Antibodies at Days 8 and 181, as Measured by HAI Assay for Vaccine-Matched Seasonal Influenza A and B Strains

    The GMFR measures the changes in immunogenicity titers or levels from Baseline within participants. Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. 95% CI was calculated based on the difference in the log-transformed values for GMT, then back transformed to the original scale for presentation.

    Time frame: Day 1 (Baseline), Day 8 and Day 181

  3. Phase 2 NH and Phase 2 Extension: Percentage of Participants With Seroconversion, as Measured by HAI Assay for Vaccine-Matched Seasonal Influenza A and B

    Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. Seroconversion at a participant level was defined as (a) if lower limit of quantification (LLOQ) was 1:10, a post-baseline titer ≥1:40 if baseline was \<1:10 or a 4-fold or greater rise from baseline if baseline was ≥1:10 in anti-HA antibodies; or (b) if LLOQ was \>1:10, a post-baseline titer ≥4 x LLOQ if baseline was \<LLOQ, or 4-fold or greater increase from baseline if baseline was ≥LLOQ in anti-HA antibodies.

    Time frame: Day 29

  4. Phase 2 NH and Phase 2 Extension: GMFR of Anti-HA Antibodies at Day 29, as Measured by HAI Assay for Vaccine-Matched Seasonal Influenza A and B Strains

    The GMFR measures the changes in immunogenicity titers or levels from Baseline within participants. Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. 95% CI was calculated based on the difference in the log-transformed values for GMFR, then back transformed to the original scale for presentation.

    Time frame: Day 29

  5. Phase 2 NH and Phase 2 Extension: Percentage of Participants With HAI Titer ≥1:40 at Day 29

    Time frame: Day 29

07

Results

Posted Oct 27, 2023

Participant flow

This study was conducted at 20 centers in the United States. The vaccines used in the study were based on the influenza virus strains recommended by the World Health Organization for the southern and northern hemispheres.

Participant flow — Overall Study
MilestonePhase 1/2: PlaceboPhase 1/2: mRNA-1010 50 ugPhase 1/2: mRNA-1010 100 ugPhase 1/2: mRNA-1010 200 ugPhase 2 NH: Afluria Quadrivalent 60 ugPhase 2 NH: mRNA-1010 25 ugPhase 2 NH: mRNA-1010 50 ugPhase 2 NH: mRNA-1010 100 ugPhase 2 Extension: Afluria Quadrivalent 60 ugPhase 2 Extension: mRNA-1010 6.25 ugPhase 2 Extension: mRNA-1010 12.5 ugPhase 2 Extension: mRNA-1010 25 ug
Started454545455315314914851505150
Received at least 1 dose of investigational product454545455315114714751505049
Safety analysis set454546445415014714751505049
Solicited safety set444546445314914614551505049
Per-protocol (pp) set414344415214413814148494746
Completed403942385013513313946474541
Not completed56373181695369
Withdrew: Death100000010100
Withdrew: Lost to follow-up34231101174238
Withdrew: Withdrawal by subject121428511031

Outcome measures

PrimaryNumber of Participants With Solicited Local and Systemic ARs

Solicited ARs (local and systemic) were collected in the electronic diary (eDiary). Local ARs included: pain at injection site, erythema (redness) at injection site, swelling/induration (hardness) at injection site, and localized axillary swelling or tenderness ipsilateral to the injection arm. Systemic ARs included: headache, fatigue, myalgia (muscle aches all over the body), arthralgia (aching in several joints), nausea/vomiting, rash, body temperature (potentially fever), and chills. Solicited ARs (local and systemic) considered causally related to injection were graded 0-4; lower score indicates lower severity and a higher score indicates greater severity. Note, not all solicited ARs were considered adverse events (AEs). The Investigator reviewed whether the solicited AR was also to be recorded as an AE. Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is in Reported "Adverse Events" section and presented by Phase/dose group.

Time frame:
7 days after vaccination
Reported as:
Count of participants · Participants
Number of Participants With Solicited Local and Systemic ARs
ParticipantsPlaceboAfluria Quadrivalent 60 ugmRNA-1010 6.25 ugmRNA-1010 12.5 ugmRNA-1010 25 ugmRNA-1010 50 ugmRNA-1010 100 ugmRNA-1010 200 ugmRNA-1010 >= 50 ug Overall
Grade 1124322167665447116
Grade 2516171281708617173
Grade 314441531451894
Grade 4000000000
PrimaryNumber of Participants With Unsolicited AEs

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. A treatment-emergent AE (TEAE) was defined as any event not present before exposure to vaccine or any event already present that worsens in intensity or frequency after exposure. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsens from baseline and is considered clinically significant in the medical and scientific judgment of the Investigator. A summary of SAEs and all nonserious AEs ("Other") reported up to the end of the study, regardless of causality, is located in the Reported "Adverse Events" section and presented by each Phase and dose group separately.

Time frame:
Up to 28 days after vaccination
Reported as:
Count of participants · Participants
Number of Participants With Unsolicited AEs
ParticipantsPlaceboAfluria Quadrivalent 60 ugmRNA-1010 6.25 ugmRNA-1010 12.5 ugmRNA-1010 25 ugmRNA-1010 50 ugmRNA-1010 100 ugmRNA-1010 200 ugmRNA-1010 >= 50 ug Overall
All62017144742461098
Serious101001203
Nonserious52016144741441095
PrimaryNumber of Participants With SAEs, AEs of Special Interest (AESIs), Medically Attended AEs (MAAEs)

An SAE was defined as any AE that resulted in death, is life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability/permanent damage, was a congenital anomaly/birth defect, or was an important medical event. AESIs included thrombocytopenia, new onset of or worsening of the protocol specified neurologic diseases, anaphylaxis, and myocarditis/pericarditis. An MAAE is an AE that leads to an unscheduled visit to an healthcare practitioner. This would include visits to a study site for unscheduled assessments (for example, abnormal laboratory follow-up, and/or COVID-19 and visits to healthcare practitioners external to the study site (for example, urgent care, primary care physician). A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section and presented by each Phase and dose group separately.

Time frame:
Up to 6 months (end of study)
Reported as:
Count of participants · Participants
Number of Participants With SAEs, AEs of Special Interest (AESIs), Medically Attended AEs (MAAEs)
ParticipantsPlaceboAfluria Quadrivalent 60 ugmRNA-1010 6.25 ugmRNA-1010 12.5 ugmRNA-1010 25 ugmRNA-1010 50 ugmRNA-1010 100 ugmRNA-1010 200 ugmRNA-1010 >= 50 ug
SAE2220354110
AESI000000000
MAAE1027181558506212124
PrimaryPhase 1/2: Geometric Mean Titer (GMT) of Anti-Hemagglutinin (HA) Antibodies at Day 29, as Measured by Hemagglutination Inhibition (HAI) Assay for Vaccine-Matched Seasonal Influenza A and B Strains

Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. GMT 95% confidence interval (CI) was calculated based on the t-distribution of the log-transformed values then back transformed to the original scale for presentation.

Time frame:
Day 29
Reported as:
Geometric mean · Titer
Phase 1/2: Geometric Mean Titer (GMT) of Anti-Hemagglutinin (HA) Antibodies at Day 29, as Measured by Hemagglutination Inhibition (HAI) Assay for Vaccine-Matched Seasonal Influenza A and B Strains
TiterPhase 1/2: PlaceboPhase 1/2: mRNA-1010 50 ugPhase 1/2: mRNA-1010 100 ugPhase 1/2: mRNA-1010 200 ug
H1N158.50 (39.17 to 87.38)410.71 (262.55 to 642.47)331.06 (214.34 to 511.34)598.22 (370.14 to 966.84)
H3N256.49 (38.27 to 83.36)376.02 (272.52 to 518.81)325.07 (234.58 to 450.47)537.26 (386.28 to 747.26)
Victoria-lineage111.14 (75.41 to 163.80)237.44 (178.78 to 315.34)169.92 (122.03 to 236.60)281.00 (213.37 to 370.06)
Yamagata-lineage103.94 (66.83 to 161.65)379.02 (277.02 to 518.57)319.07 (218.60 to 465.73)456.36 (341.14 to 610.50)
PrimaryPhase 2 NH: GMT of HA Antibodies at Day 29, as Measured by HAI Assay for Vaccine-Matched Seasonal Influenza A and B Strains

Humoral immunogenicity relative to that of the active comparator (afluria quadrivalent) was assessed against vaccine-matched Influenza A and B strains at Day 29. Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. GMT 95% CI was calculated based on the t-distribution of the log-transformed values then back transformed to the original scale for presentation.

Time frame:
Day 29
Reported as:
Geometric mean · titer
Phase 2 NH: GMT of HA Antibodies at Day 29, as Measured by HAI Assay for Vaccine-Matched Seasonal Influenza A and B Strains
titerPhase 2 NH: Afluria Quadrivalent 60 ugPhase 2 NH: mRNA-1010 25 ugPhase 2 NH: mRNA-1010 50 ugPhase 2 NH: mRNA-1010 100 ug
H1N1164.00 (120.18 to 223.81)298.88 (247.21 to 361.36)422.24 (347.72 to 512.73)443.62 (366.58 to 536.85)
H3N285.54 (64.33 to 113.74)153.43 (128.99 to 182.50)187.08 (156.64 to 223.43)215.23 (180.75 to 256.28)
Victoria-lineage147.47 (119.98 to 181.24)100.51 (88.63 to 114.00)129.56 (113.92 to 147.36)123.17 (108.47 to 139.85)
Yamagata-lineage193.08 (155.16 to 240.27)215.19 (188.30 to 245.92)230.66 (201.23 to 264.40)231.44 (202.38 to 264.68)
Statistical analysis
  • Phase 2 NH: Afluria Quadrivalent 60 ug vs Phase 2 NH: mRNA-1010 25 ug · Ratio: 1.82 · 95% CI 1.27 to 2.61The 2 sided 95% assessed the difference in immune response between the mRNA-1010 compared with the active comparator, Afluria Quadrivalent, at Day 29.
  • Phase 2 NH: Afluria Quadrivalent 60 ug vs Phase 2 NH: mRNA-1010 50 ug · Ratio: 2.57 · 95% CI 1.79 to 3.70The 2 sided 95% assessed the difference in immune response between the mRNA-1010 compared with the active comparator, Afluria Quadrivalent, at Day 29.
  • Phase 2 NH: Afluria Quadrivalent 60 ug vs Phase 2 NH: mRNA-1010 100 ug · Ratio: 2.70 · 95% CI 1.88 to 3.88The 2 sided 95% assessed the difference in immune response between the mRNA-1010 compared with the active comparator, Afluria Quadrivalent, at Day 29.
  • Phase 2 NH: Afluria Quadrivalent 60 ug vs Phase 2 NH: mRNA-1010 25 ug · Ratio: 1.79 · 95% CI 1.29 to 2.50The 2 sided 95% assessed the difference in immune response between the mRNA-1010 compared with the active comparator, Afluria Quadrivalent, at Day 29.
  • Phase 2 NH: Afluria Quadrivalent 60 ug vs Phase 2 NH: mRNA-1010 50 ug · Ratio: 2.19 · 95% CI 1.57 to 3.05The 2 sided 95% assessed the difference in immune response between the mRNA-1010 compared with the active comparator, Afluria Quadrivalent, at Day 29.
  • Phase 2 NH: Afluria Quadrivalent 60 ug vs Phase 2 NH: mRNA-1010 100 ug · Ratio: 2.52 · 95% CI 1.81 to 3.50The 2 sided 95% assessed the difference in immune response between the mRNA-1010 compared with the active comparator, Afluria Quadrivalent, at Day 29.
  • Phase 2 NH: Afluria Quadrivalent 60 ug vs Phase 2 NH: mRNA-1010 25 ug · Ratio: 0.68 · 95% CI 0.54 to 0.87The 2 sided 95% assessed the difference in immune response between the mRNA-1010 compared with the active comparator, Afluria Quadrivalent, at Day 29.
  • Phase 2 NH: Afluria Quadrivalent 60 ug vs Phase 2 NH: mRNA-1010 50 ug · Ratio: 0.88 · 95% CI 0.69 to 1.12The 2 sided 95% assessed the difference in immune response between the mRNA-1010 compared with the active comparator, Afluria Quadrivalent, at Day 29.
  • Phase 2 NH: Afluria Quadrivalent 60 ug vs Phase 2 NH: mRNA-1010 100 ug · Ratio: 0.84 · 95% CI 0.66 to 1.06The 2 sided 95% assessed the difference in immune response between the mRNA-1010 compared with the active comparator, Afluria Quadrivalent, at Day 29.
  • Phase 2 NH: Afluria Quadrivalent 60 ug vs Phase 2 NH: mRNA-1010 25 ug · Ratio: 1.11 · 95% CI 0.86 to 1.44The 2 sided 95% assessed the difference in immune response between the mRNA-1010 compared with the active comparator, Afluria Quadrivalent, at Day 29.
  • Phase 2 NH: Afluria Quadrivalent 60 ug vs Phase 2 NH: mRNA-1010 50 ug · Ratio: 1.19 · 95% CI 0.93 to 1.54The 2 sided 95% assessed the difference in immune response between the mRNA-1010 compared with the active comparator, Afluria Quadrivalent, at Day 29.
  • Phase 2 NH: Afluria Quadrivalent 60 ug vs Phase 2 NH: mRNA-1010 100 ug · Ratio: 1.20 · 95% CI 0.93 to 1.55The 2 sided 95% assessed the difference in immune response between the mRNA-1010 compared with the active comparator, Afluria Quadrivalent, at Day 29.
PrimaryPhase 2 Extension: GMT of HA Antibodies at Day 29, as Measured by HAI Assay for Vaccine-Matched Seasonal Influenza A and B Strains

Humoral immunogenicity relative to that of the active comparator (afluria quadrivalent) was assessed against vaccine-matched Influenza A and B strains at Day 29. Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. GMT 95% CI was calculated based on the t-distribution of the log-transformed values then back transformed to the original scale for presentation.

Time frame:
Day 29
Reported as:
Geometric mean · Titer
Phase 2 Extension: GMT of HA Antibodies at Day 29, as Measured by HAI Assay for Vaccine-Matched Seasonal Influenza A and B Strains
TiterPhase 2 Extension: Afluria Quadrivalent 60 ugPhase 2 Extension: mRNA-1010 6.25 ugPhase 2 Extension: mRNA-1010 12.5 ugPhase 2 Extension: mRNA-1010 25 ug
H1N1253.07 (180.86 to 354.12)228.02 (163.17 to 318.64)316.53 (225.12 to 445.06)471.56 (334.39 to 664.99)
H3N2114.21 (82.80 to 157.55)161.58 (117.46 to 222.27)216.32 (156.34 to 299.30)301.53 (217.28 to 418.45)
Victoria-lineage155.07 (121.65 to 197.66)55.76 (43.81 to 70.97)71.12 (55.51 to 91.11)83.46 (65.16 to 106.90)
Yamagata-lineage193.16 (147.41 to 253.12)119.54 (91.34 to 156.45)178.43 (135.33 to 235.26)144.13 (109.16 to 190.29)
Statistical analysis
  • Phase 2 Extension: Afluria Quadrivalent 60 ug vs Phase 2 Extension: mRNA-1010 6.25 ug · Ratio: 0.90 · 95% CI 0.57 to 1.44The 2 sided 95% assessed the difference in immune response between the mRNA-1010 compared with the active comparator, Afluria Quadrivalent, at Day 29.
  • Phase 2 Extension: Afluria Quadrivalent 60 ug vs Phase 2 Extension: mRNA-1010 12.5 ug · Ratio: 1.25 · 95% CI 0.78 to 2.00The 2 sided 95% assessed the difference in immune response between the mRNA-1010 compared with the active comparator, Afluria Quadrivalent, at Day 29.
  • Phase 2 Extension: Afluria Quadrivalent 60 ug vs Phase 2 Extension: mRNA-1010 25 ug · Ratio: 1.86 · 95% CI 1.16 to 2.99The 2 sided 95% assessed the difference in immune response between the mRNA-1010 compared with the active comparator, Afluria Quadrivalent, at Day 29.
  • Phase 2 Extension: Afluria Quadrivalent 60 ug vs Phase 2 Extension: mRNA-1010 6.25 ug · Ratio: 1.41 · 95% CI 0.91 to 2.21The 2 sided 95% assessed the difference in immune response between the mRNA-1010 compared with the active comparator, Afluria Quadrivalent, at Day 29.
  • Phase 2 Extension: Afluria Quadrivalent 60 ug vs Phase 2 Extension: mRNA-1010 12.5 ug · Ratio: 1.89 · 95% CI 1.21 to 2.97The 2 sided 95% assessed the difference in immune response between the mRNA-1010 compared with the active comparator, Afluria Quadrivalent, at Day 29.
  • Phase 2 Extension: Afluria Quadrivalent 60 ug vs Phase 2 Extension: mRNA-1010 25 ug · Ratio: 2.64 · 95% CI 1.68 to 4.14The 2 sided 95% assessed the difference in immune response between the mRNA-1010 compared with the active comparator, Afluria Quadrivalent, at Day 29.
  • Phase 2 Extension: Afluria Quadrivalent 60 ug vs Phase 2 Extension: mRNA-1010 6.25 ug · Ratio: 0.36 · 95% CI 0.26 to 0.50The 2 sided 95% assessed the difference in immune response between the mRNA-1010 compared with the active comparator, Afluria Quadrivalent, at Day 29.
  • Phase 2 Extension: Afluria Quadrivalent 60 ug vs Phase 2 Extension: mRNA-1010 12.5 ug · Ratio: 0.46 · 95% CI 0.33 to 0.64The 2 sided 95% assessed the difference in immune response between the mRNA-1010 compared with the active comparator, Afluria Quadrivalent, at Day 29.
  • Phase 2 Extension: Afluria Quadrivalent 60 ug vs Phase 2 Extension: mRNA-1010 25 ug · Ratio: 0.54 · 95% CI 0.38 to 0.76The 2 sided 95% assessed the difference in immune response between the mRNA-1010 compared with the active comparator, Afluria Quadrivalent, at Day 29.
  • Phase 2 Extension: Afluria Quadrivalent 60 ug vs Phase 2 Extension: mRNA-1010 6.25 ug · Ratio: 0.62 · 95% CI 0.43 to 0.90The 2 sided 95% assessed the difference in immune response between the mRNA-1010 compared with the active comparator, Afluria Quadrivalent, at Day 29.
  • Phase 2 Extension: Afluria Quadrivalent 60 ug vs Phase 2 Extension: mRNA-1010 12.5 ug · Ratio: 0.92 · 95% CI 0.63 to 1.35The 2 sided 95% assessed the difference in immune response between the mRNA-1010 compared with the active comparator, Afluria Quadrivalent, at Day 29.
  • Phase 2 Extension: Afluria Quadrivalent 60 ug vs Phase 2 Extension: mRNA-1010 25 ug · Ratio: 0.75 · 95% CI 0.51 to 1.09The 2 sided 95% assessed the difference in immune response between the mRNA-1010 compared with the active comparator, Afluria Quadrivalent, at Day 29.
PrimaryPhase 1/2: Percentage of Participants With Seroconversion, as Measured by HAI Assay for Vaccine-Matched Seasonal Influenza A and B

Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. Seroconversion at a participant level was defined as (a) if lower limit of quantification (LLOQ) was 1:10, a post-baseline titer ≥1:40 if baseline was \<1:10 or a 4-fold or greater rise from baseline if baseline was ≥1:10 in anti-HA antibodies; or (b) if LLOQ was \>1:10, a post-baseline titer ≥4 x LLOQ if baseline was \<LLOQ, or 4-fold or greater increase from baseline if baseline was ≥LLOQ in anti-HA antibodies.

Time frame:
Day 29
Reported as:
Number · percentage of participants
Phase 1/2: Percentage of Participants With Seroconversion, as Measured by HAI Assay for Vaccine-Matched Seasonal Influenza A and B
percentage of participantsPhase 1/2: PlaceboPhase 1/2: mRNA-1010 50 ugPhase 1/2: mRNA-1010 100 ugPhase 1/2: mRNA-1010 200 ug
H1N14.9 (0.60 to 16.53)67.4 (51.46 to 80.92)81.8 (67.29 to 91.81)90.2 (76.87 to 97.28)
H3N22.4 (0.06 to 12.86)81.4 (66.60 to 91.61)75.0 (59.66 to 86.81)75.6 (59.70 to 87.64)
Victoria-lineage2.4 (0.06 to 12.86)14.0 (5.30 to 27.93)15.9 (6.64 to 30.07)25.0 (12.69 to 41.20)
Yamagata-lineage2.4 (0.06 to 12.86)41.9 (27.01 to 57.87)50.0 (34.56 to 65.44)51.2 (35.13 to 67.12)
PrimaryPhase 1/2: Geometric Mean Fold-Rise (GMFR) of Anti-HA Antibodies at Day 29, as Measured by HAI Assay for Vaccine-Matched Seasonal Influenza A and B Strains

The GMFR measures the changes in immunogenicity titers or levels from Baseline within participants. Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. 95% CI was calculated based on the difference in the log-transformed values for GMFR, then back transformed to the original scale for presentation.

Time frame:
Day 1 (Baseline), Day 29
Reported as:
Number · ratio
Phase 1/2: Geometric Mean Fold-Rise (GMFR) of Anti-HA Antibodies at Day 29, as Measured by HAI Assay for Vaccine-Matched Seasonal Influenza A and B Strains
ratioPhase 1/2: PlaceboPhase 1/2: mRNA-1010 50 ugPhase 1/2: mRNA-1010 100 ugPhase 1/2: mRNA-1010 200 ug
H1N11.08 (0.91 to 1.29)7.50 (5.00 to 11.26)8.69 (6.03 to 12.50)11.05 (7.59 to 16.11)
H3N21.05 (0.80 to 1.39)7.16 (5.19 to 9.88)6.43 (4.54 to 9.10)7.13 (5.12 to 9.93)
Victoria-lineage0.98 (0.80 to 1.20)1.95 (1.61 to 2.37)1.86 (1.36 to 2.53)2.03 (1.50 to 2.75)
Yamagata-lineage0.92 (0.81 to 1.05)3.04 (2.34 to 3.96)3.78 (2.70 to 5.28)3.55 (2.47 to 5.11)
PrimaryPhase 2 NH: Percentage of Participants With Seroconversion, as Measured by HAI Assay for Vaccine-Matched Seasonal Influenza A and B

Humoral immunogenicity relative to that of the active comparator (afluria quadrivalent) was assessed against vaccine-matched Influenza A and B strains at Day 29. Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. Seroconversion at a participant level was defined as (a) if LLOQ was 1:10, a post-baseline titer ≥1:40 if baseline was \<1:10 or a 4-fold or greater rise from baseline if baseline was ≥1:10 in anti-HA antibodies; or (b) if LLOQ was \>1:10, a post-baseline titer ≥4 x LLOQ if baseline was \<LLOQ, or 4-fold or greater increase from baseline if baseline was ≥LLOQ in anti-HA antibodies. 95% CI was calculated using the Clopper-Pearson method

Time frame:
Day 29
Reported as:
Number · percentage of participants
Phase 2 NH: Percentage of Participants With Seroconversion, as Measured by HAI Assay for Vaccine-Matched Seasonal Influenza A and B
percentage of participantsPhase 2 NH: Afluria Quadrivalent 60 ugPhase 2 NH: mRNA-1010 25 ugPhase 2 NH: mRNA-1010 50 ugPhase 2 NH: mRNA-1010 100 ug
H1N159.6 (45.10 to 72.99)72.2 (64.15 to 79.36)84.8 (77.68 to 90.33)85.8 (78.95 to 91.12)
H3N240.4 (27.01 to 54.90)66.0 (57.62 to 73.65)71.7 (63.45 to 79.07)78.7 (71.04 to 85.16)
Victoria-lineage32.7 (20.33 to 47.11)22.9 (16.33 to 30.65)33.3 (25.54 to 41.86)37.1 (29.13 to 45.71)
Yamagata-lineage32.7 (20.33 to 47.11)41.7 (33.52 to 50.17)47.8 (39.26 to 56.49)51.8 (43.21 to 60.26)
Statistical analysis
  • Phase 2 NH: Afluria Quadrivalent 60 ug vs Phase 2 NH: mRNA-1010 25 ug · Percent difference: 12.61 · 95% CI -2.00 to 27.93Seroconversion percent difference of mRNA-1010 - Afluria Quadrivalent. 95% CI was calculated using the Miettinen-Nurminen (score) method.
  • Phase 2 NH: Afluria Quadrivalent 60 ug vs Phase 2 NH: mRNA-1010 50 ug · Percent difference: 25.17 · 95% CI 11.18 to 39.89Seroconversion percent difference of mRNA-1010 - Afluria Quadrivalent. 95% CI was calculated using the Miettinen-Nurminen (score) method.
  • Phase 2 NH: Afluria Quadrivalent 60 ug vs Phase 2 NH: mRNA-1010 100 ug · Percent difference: 26.20 · 95% CI 12.33 to 40.84Seroconversion percent difference of mRNA-1010 - Afluria Quadrivalent. 95% CI was calculated using the Miettinen-Nurminen (score) method.
  • Phase 2 NH: Afluria Quadrivalent 60 ug vs Phase 2 NH: mRNA-1010 25 ug · Percent difference: 25.59 · 95% CI 9.82 to 40.13Seroconversion percent difference of mRNA-1010 - Afluria Quadrivalent. 95% CI was calculated using the Miettinen-Nurminen (score) method.
  • Phase 2 NH: Afluria Quadrivalent 60 ug vs Phase 2 NH: mRNA-1010 50 ug · Percent difference: 31.35 · 95% CI 15.66 to 45.73Seroconversion percent difference of mRNA-1010 - Afluria Quadrivalent. 95% CI was calculated using the Miettinen-Nurminen (score) method.
  • Phase 2 NH: Afluria Quadrivalent 60 ug vs Phase 2 NH: mRNA-1010 100 ug · Percent difference: 38.34 · 95% CI 22.98 to 52.30Seroconversion percent difference of mRNA-1010 - Afluria Quadrivalent. 95% CI was calculated using the Miettinen-Nurminen (score) method.
  • Phase 2 NH: Afluria Quadrivalent 60 ug vs Phase 2 NH: mRNA-1010 25 ug · Percent difference: -9.78 · 95% CI -24.83 to 3.79Seroconversion percent difference of mRNA-1010 - Afluria Quadrivalent. 95% CI was calculated using the Miettinen-Nurminen (score) method.
  • Phase 2 NH: Afluria Quadrivalent 60 ug vs Phase 2 NH: mRNA-1010 50 ug · Percent difference: 0.64 · 95% CI -14.91 to 14.73Seroconversion percent difference of mRNA-1010 - Afluria Quadrivalent. 95% CI was calculated using the Miettinen-Nurminen (score) method.
  • Phase 2 NH: Afluria Quadrivalent 60 ug vs Phase 2 NH: mRNA-1010 100 ug · Percent difference: 4.45 · 95% CI -11.19 to 18.59Seroconversion percent difference of mRNA-1010 - Afluria Quadrivalent. 95% CI was calculated using the Miettinen-Nurminen (score) method.
  • Phase 2 NH: Afluria Quadrivalent 60 ug vs Phase 2 NH: mRNA-1010 25 ug · Percent difference: 8.97 · 95% CI -6.72 to 23.09Seroconversion percent difference of mRNA-1010 - Afluria Quadrivalent. 95% CI was calculated using the Miettinen-Nurminen (score) method.
  • Phase 2 NH: Afluria Quadrivalent 60 ug vs Phase 2 NH: mRNA-1010 50 ug · Percent difference: 15.13 · 95% CI -0.74 to 29.37Seroconversion percent difference of mRNA-1010 - Afluria Quadrivalent. 95% CI was calculated using the Miettinen-Nurminen (score) method.
  • Phase 2 NH: Afluria Quadrivalent 60 ug vs Phase 2 NH: mRNA-1010 100 ug · Percent difference: 19.08 · 95% CI 3.22 to 33.22Seroconversion percent difference of mRNA-1010 - Afluria Quadrivalent. 95% CI was calculated using the Miettinen-Nurminen (score) method.
PrimaryPhase 2 Extension: Percentage of Participants With Seroconversion, as Measured by HAI Assay for Vaccine-Matched Seasonal Influenza A and B

Humoral immunogenicity relative to that of the active comparator (afluria quadrivalent) was assessed against vaccine-matched Influenza A and B strains at Day 29. Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. Seroconversion at a participant level was defined as (a) if LLOQ was 1:10, a post-baseline titer ≥1:40 if baseline was \<1:10 or a 4-fold or greater rise from baseline if baseline was ≥1:10 in anti-HA antibodies; or (b) if LLOQ was \>1:10, a post-baseline titer ≥4 x LLOQ if baseline was \<LLOQ, or 4-fold or greater increase from baseline if baseline was ≥LLOQ in anti-HA antibodies. 95% CI was calculated using the Clopper-Pearson method

Time frame:
Day 29
Reported as:
Number · percentage of participants
Phase 2 Extension: Percentage of Participants With Seroconversion, as Measured by HAI Assay for Vaccine-Matched Seasonal Influenza A and B
percentage of participantsAfluria Quadrivalent 60 ugmRNA-1010 6.25 ugmRNA-1010 12.5 ugmRNA-1010 25 ug
H1N150.0 (35.23 to 64.77)59.2 (44.21 to 73.00)68.1 (52.88 to 80.91)73.9 (58.87 to 85.73)
H3N243.8 (29.48 to 58.82)44.9 (30.67 to 59.77)66.0 (50.69 to 79.14)80.4 (66.09 to 90.64)
Victoria-lineage47.9 (33.29 to 62.81)10.2 (3.40 to 22.23)21.7 (10.95 to 36.36)28.3 (15.99 to 43.46)
Yamagata-lineage47.9 (33.29 to 62.81)24.5 (13.34 to 38.87)43.5 (28.93 to 58.89)39.1 (25.09 to 54.63)
Statistical analysis
  • Afluria Quadrivalent 60 ug vs mRNA-1010 6.25 ug · Percent difference: 9.18 · 95% CI -10.62 to 28.31Seroconversion percent difference of mRNA-1010 - Afluria Quadrivalent. 95% CI was calculated using the Miettinen-Nurminen (score) method.
  • Afluria Quadrivalent 60 ug vs mRNA-1010 12.5 ug · Percent difference: 18.09 · 95% CI -1.81 to 36.61Seroconversion percent difference of mRNA-1010 - Afluria Quadrivalent. 95% CI was calculated using the Miettinen-Nurminen (score) method.
  • Afluria Quadrivalent 60 ug vs mRNA-1010 25 ug · Percent difference: 23.91 · 95% CI 4.20 to 41.86Seroconversion percent difference of mRNA-1010 - Afluria Quadrivalent. 95% CI was calculated using the Miettinen-Nurminen (score) method.
  • Afluria Quadrivalent 60 ug vs mRNA-1010 6.25 ug · Percent difference: 1.15 · 95% CI -18.41 to 20.60Seroconversion percent difference of mRNA-1010 - Afluria Quadrivalent. 95% CI was calculated using the Miettinen-Nurminen (score) method.
  • Afluria Quadrivalent 60 ug vs mRNA-1010 12.5 ug · Percent difference: 22.21 · 95% CI 2.09 to 40.60Seroconversion percent difference of mRNA-1010 - Afluria Quadrivalent. 95% CI was calculated using the Miettinen-Nurminen (score) method.
  • Afluria Quadrivalent 60 ug vs mRNA-1010 25 ug · Percent difference: 36.68 · 95% CI 17.38 to 53.36Seroconversion percent difference of mRNA-1010 - Afluria Quadrivalent. 95% CI was calculated using the Miettinen-Nurminen (score) method.
  • Afluria Quadrivalent 60 ug vs mRNA-1010 6.25 ug · Percent difference: -37.71 · 95% CI -53.36 to -20.45Seroconversion percent difference of mRNA-1010 - Afluria Quadrivalent. 95% CI was calculated using the Miettinen-Nurminen (score) method.
  • Afluria Quadrivalent 60 ug vs mRNA-1010 12.5 ug · Treatment difference: -26.18 · 95% CI -43.66 to -6.90Seroconversion percent difference of mRNA-1010 - Afluria Quadrivalent. 95% CI was calculated using the Miettinen-Nurminen (score) method.
  • Afluria Quadrivalent 60 ug vs mRNA-1010 25 ug · Percent difference: -19.66 · 95% CI -37.95 to 0.11Seroconversion percent difference of mRNA-1010 - Afluria Quadrivalent. 95% CI was calculated using the Miettinen-Nurminen (score) method.
  • Afluria Quadrivalent 60 ug vs mRNA-1010 6.25 ug · Percent difference: -23.43 · 95% CI -41.09 to -4.26Seroconversion percent difference of mRNA-1010 - Afluria Quadrivalent. 95% CI was calculated using the Miettinen-Nurminen (score) method.
  • Afluria Quadrivalent 60 ug vs mRNA-1010 12.5 ug · Percent difference: -4.44 · 95% CI -24.09 to 15.59Seroconversion percent difference of mRNA-1010 - Afluria Quadrivalent. 95% CI was calculated using the Miettinen-Nurminen (score) method.
  • Afluria Quadrivalent 60 ug vs mRNA-1010 25 ug · Percent difference: -8.79 · 95% CI -28.13 to 11.27Seroconversion percent difference of mRNA-1010 - Afluria Quadrivalent. 95% CI was calculated using the Miettinen-Nurminen (score) method.
SecondaryPhase 1/2: GMT of Anti-HA Antibodies at Days 1, 8 and 181, as Measured by HAI Assay for Vaccine-Matched Seasonal Influenza A and B Strains

Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. GMT 95% CI was calculated based on the t-distribution of the log-transformed values then back transformed to the original scale for presentation.

Time frame:
Day 1 (Baseline), Day 8 and Day 181
Reported as:
Geometric mean · titer
Phase 1/2: GMT of Anti-HA Antibodies at Days 1, 8 and 181, as Measured by HAI Assay for Vaccine-Matched Seasonal Influenza A and B Strains
titerPhase 1/2: PlaceboPhase 1/2: mRNA-1010 50 ugPhase 1/2: mRNA-1010 100 ugPhase 1/2: mRNA-1010 200 ug
Day 1 (Baseline): H1N154.16 (35.85 to 81.83)54.73 (37.76 to 79.31)38.12 (28.35 to 51.26)54.12 (37.26 to 78.61)
Day 8: H1N142.05 (27.89 to 63.40)185.61 (125.31 to 274.92)163.84 (101.76 to 263.81)319.86 (208.59 to 490.50)
Day 181: H1N167.55 (41.88 to 108.96)167.28 (121.35 to 230.59)74.14 (52.08 to 105.54)159.95 (104.34 to 245.20)
Day 1 (Baseline): H3N253.68 (36.84 to 78.22)52.52 (37.35 to 73.85)50.59 (37.90 to 67.53)75.31 (50.06 to 113.30)
Day 8: H3N251.46 (37.34 to 70.91)211.76 (148.46 to 302.04)220.95 (155.08 to 314.81)345.29 (262.51 to 454.16)
Day 181: H3N267.50 (45.07 to 101.09)186.06 (136.00 to 254.55)158.74 (116.46 to 216.37)235.10 (167.17 to 330.64)
Day 1 (Baseline): Victoria-lineage113.97 (76.71 to 169.33)121.61 (86.46 to 171.06)91.41 (64.64 to 129.27)137.99 (95.73 to 198.91)
Day 8: Victoria-lineage34.65 (23.93 to 50.17)91.27 (68.41 to 121.78)113.14 (81.85 to 156.40)122.10 (88.63 to 168.20)
Day 181: Victoria-lineage37.59 (26.09 to 54.17)76.56 (55.37 to 105.87)72.27 (53.70 to 97.26)70.62 (48.32 to 103.19)
Day 1 (Baseline): Yamagata-lineage113.13 (70.09 to 182.60)124.60 (86.34 to 179.83)84.47 (55.85 to 127.75)128.43 (81.44 to 202.53)
Day 8: Yamagata-lineage54.68 (36.21 to 82.59)118.85 (90.96 to 155.29)116.79 (81.49 to 167.37)194.38 (141.31 to 267.38)
Day 181: Yamagata-lineage55.08 (36.30 to 83.57)106.23 (79.98 to 141.08)69.87 (52.76 to 92.54)112.06 (73.69 to 170.39)
SecondaryPhase 1/2: GMFR of Anti-HA Antibodies at Days 8 and 181, as Measured by HAI Assay for Vaccine-Matched Seasonal Influenza A and B Strains

The GMFR measures the changes in immunogenicity titers or levels from Baseline within participants. Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. 95% CI was calculated based on the difference in the log-transformed values for GMT, then back transformed to the original scale for presentation.

Time frame:
Day 1 (Baseline), Day 8 and Day 181
Reported as:
Number · ratio
Phase 1/2: GMFR of Anti-HA Antibodies at Days 8 and 181, as Measured by HAI Assay for Vaccine-Matched Seasonal Influenza A and B Strains
ratioPhase 1/2: PlaceboPhase 1/2: mRNA-1010 50 ugPhase 1/2: mRNA-1010 100 ugPhase 1/2: mRNA-1010 200 ug
Day 8: H1N10.78 (0.62 to 0.98)3.48 (2.35 to 5.14)4.30 (2.76 to 6.69)5.91 (3.83 to 9.11)
Day 181: H1N11.21 (0.87 to 1.67)2.99 (1.95 to 4.57)2.18 (1.51 to 3.14)2.92 (2.11 to 4.04)
Day 8: H3N20.96 (0.73 to 1.25)4.21 (2.77 to 6.40)4.37 (2.73 to 6.99)4.58 (2.90 to 7.25)
Day 181: H3N21.27 (0.89 to 1.82)3.24 (2.37 to 4.41)3.27 (2.28 to 4.70)3.09 (2.14 to 4.46)
Day 8: Victoria-lineage0.30 (0.22 to 0.41)0.77 (0.54 to 1.10)1.24 (0.86 to 1.77)0.85 (0.55 to 1.30)
Day 181: Victoria-lineage0.34 (0.25 to 0.48)0.54 (0.37 to 0.80)0.82 (0.59 to 1.15)0.48 (0.32 to 0.70)
Day 8: Yamagata-lineage0.48 (0.37 to 0.63)0.98 (0.72 to 1.32)1.38 (1.00 to 1.90)1.51 (1.05 to 2.17)
Day 181: Yamagata-lineage0.53 (0.40 to 0.69)0.77 (0.56 to 1.07)0.96 (0.67 to 1.37)0.85 (0.66 to 1.09)
SecondaryPhase 2 NH and Phase 2 Extension: Percentage of Participants With Seroconversion, as Measured by HAI Assay for Vaccine-Matched Seasonal Influenza A and B

Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. Seroconversion at a participant level was defined as (a) if lower limit of quantification (LLOQ) was 1:10, a post-baseline titer ≥1:40 if baseline was \<1:10 or a 4-fold or greater rise from baseline if baseline was ≥1:10 in anti-HA antibodies; or (b) if LLOQ was \>1:10, a post-baseline titer ≥4 x LLOQ if baseline was \<LLOQ, or 4-fold or greater increase from baseline if baseline was ≥LLOQ in anti-HA antibodies.

Time frame:
Day 29
Reported as:
Number · Percentage of participants
Phase 2 NH and Phase 2 Extension: Percentage of Participants With Seroconversion, as Measured by HAI Assay for Vaccine-Matched Seasonal Influenza A and B
Percentage of participantsPhase 2 NH: Afluria Quadrivalent 60 ugPhase 2 NH: mRNA-1010 25 ugPhase 2 NH: mRNA-1010 50 ugPhase 2 NH: mRNA-1010 100 ugPhase 2 Extension: Afluria Quadrivalent 60 ugPhase 2 Extension: mRNA-1010 6.25 ugPhase 2 NH: mRNA-1010 12.5 ugPhase 2 Extension: mRNA-1010 25 ug
H1N159.6 (45.10 to 72.99)72.2 (64.15 to 79.36)84.8 (77.68 to 90.33)85.8 (78.95 to 91.12)50.0 (35.23 to 64.77)59.2 (44.21 to 73.00)68.1 (52.88 to 80.91)73.9 (58.87 to 85.73)
H3N240.4 (27.01 to 54.90)66.0 (57.62 to 73.65)71.7 (63.45 to 79.07)78.7 (71.04 to 85.16)43.8 (29.48 to 58.82)44.9 (30.67 to 59.77)66.0 (50.69 to 79.14)80.4 (66.09 to 90.64)
Victoria-lineage32.7 (20.33 to 47.11)22.9 (16.33 to 30.65)33.3 (25.54 to 41.86)37.1 (29.13 to 45.71)47.9 (33.29 to 62.81)10.2 (3.40 to 22.23)21.7 (10.95 to 36.36)28.3 (15.99 to 43.46)
Yamagata-lineage32.7 (20.33 to 47.11)41.7 (33.52 to 50.17)47.8 (39.26 to 56.49)51.8 (43.21 to 60.26)47.9 (33.29 to 62.81)24.5 (13.34 to 38.87)43.5 (28.93 to 58.89)39.1 (25.09 to 54.63)
SecondaryPhase 2 NH and Phase 2 Extension: GMFR of Anti-HA Antibodies at Day 29, as Measured by HAI Assay for Vaccine-Matched Seasonal Influenza A and B Strains

The GMFR measures the changes in immunogenicity titers or levels from Baseline within participants. Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. 95% CI was calculated based on the difference in the log-transformed values for GMFR, then back transformed to the original scale for presentation.

Time frame:
Day 29
Reported as:
Number · ratio
Phase 2 NH and Phase 2 Extension: GMFR of Anti-HA Antibodies at Day 29, as Measured by HAI Assay for Vaccine-Matched Seasonal Influenza A and B Strains
ratioPhase 2 NH: Afluria Quadrivalent 60 ugPhase 2 NH: mRNA-1010 25 ugPhase 2 NH: mRNA-1010 50 ugPhase 2 NH: mRNA-1010 100 ugPhase 2 Extension: Afluria Quadrivalent 60 ugPhase 2 Extension: mRNA-1010 6.25 ugPhase 2 Extension: mRNA-1010 12.5 ugPhase 2 Extension: mRNA-1010 25 ug
H1N14.19 (2.82 to 6.23)7.64 (6.22 to 9.38)12.15 (9.38 to 15.73)11.96 (9.81 to 14.58)6.08 (3.84 to 9.64)6.03 (4.22 to 8.61)7.21 (4.90 to 10.63)12.58 (7.95 to 19.90)
H3N23.17 (2.20 to 4.58)6.28 (5.02 to 7.84)8.17 (6.63 to 10.06)8.70 (7.22 to 10.48)3.78 (2.56 to 5.58)4.51 (3.15 to 6.46)6.66 (4.57 to 9.69)9.30 (6.11 to 14.17)
Victoria-lineage3.30 (2.13 to 5.11)2.27 (2.00 to 2.58)3.06 (2.60 to 3.60)2.79 (2.47 to 3.15)3.91 (2.66 to 5.76)1.69 (1.30 to 2.20)1.84 (1.39 to 2.43)2.47 (1.76 to 3.46)
Yamagata-lineage3.07 (2.19 to 4.29)3.33 (2.85 to 3.90)3.73 (3.09 to 4.51)3.67 (3.15 to 4.27)3.72 (2.70 to 5.15)2.29 (1.67 to 3.14)3.03 (2.18 to 4.21)3.08 (2.08 to 4.55)
SecondaryPhase 2 NH and Phase 2 Extension: Percentage of Participants With HAI Titer ≥1:40 at Day 29
Time frame:
Day 29
Reported as:
Number · percentage of participants
Phase 2 NH and Phase 2 Extension: Percentage of Participants With HAI Titer ≥1:40 at Day 29
percentage of participantsPhase 2 NH: Afluria Quadrivalent 60 ugPhase 2 NH: mRNA-1010 25 ugPhase 2 NH: mRNA-1010 50 ugPhase 2 NH: mRNA-1010 100 ugPhase 2 Extension: Afluria Quadrivalent 60 ugPhase 2 Extension: mRNA-1010 6.25 ugPhase 2 Extension: mRNA-1010 12.5 ugPhase 2 Extension: mRNA-1010 25 ug
H1N192.3 (81.46 to 97.86)97.2 (93.04 to 99.24)97.1 (92.74 to 99.20)98.6 (94.97 to 99.83)95.8 (85.75 to 99.49)93.9 (83.13 to 98.72)95.7 (85.46 to 99.48)97.8 (88.47 to 99.94)
H3N290.4 (78.97 to 96.80)91.0 (85.06 to 95.11)91.3 (85.30 to 95.43)91.5 (85.61 to 95.52)81.3 (67.37 to 91.05)89.8 (77.77 to 96.60)93.6 (82.46 to 98.66)97.8 (88.47 to 99.94)
Victoria-lineage96.2 (86.79 to 99.53)91.7 (85.90 to 95.62)90.6 (84.43 to 94.89)91.4 (85.51 to 95.49)100.0 (92.60 to 100.0)75.5 (61.13 to 86.66)89.1 (76.43 to 96.38)82.6 (68.58 to 92.18)
Yamagata-lineage96.2 (86.79 to 99.51)99.3 (96.19 to 99.98)96.4 (91.75 to 98.81)97.2 (92.90 to 99.22)97.9 (88.93 to 99.95)93.9 (83.13 to 98.72)95.7 (85.16 to 99.47)91.3 (79.21 to 97.58)

Adverse events

Collected over Up to 6 months (Day 181, end of study). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1/2: Placebo1/45 (2.2%)2/45 (4.4%)26/45 (57.8%)
Phase 1/2: mRNA-1010 50 ug0/45 (0%)0/45 (0%)39/45 (86.7%)
Phase 1/2: mRNA-1010 100 ug0/46 (0%)0/46 (0%)44/46 (95.7%)
Phase 1/2: mRNA-1010 200 ug0/44 (0%)1/44 (2.3%)42/44 (95.5%)
Phase 2 NH: Afluria Quadrivalent 60 ug0/54 (0%)1/54 (1.9%)37/54 (68.5%)
Phase 2 NH: mRNA-1010 25 ug0/150 (0%)3/150 (2%)130/150 (86.7%)
Phase 2 NH: mRNA-1010 50 ug0/147 (0%)5/147 (3.4%)133/147 (90.5%)
Phase 2 NH: mRNA-1010 100 ug1/147 (0.7%)4/147 (2.7%)133/147 (90.5%)
Phase 2 Extension: Afluria Quadrivalent 60 ug0/51 (0%)1/51 (2%)33/51 (64.7%)
Phase 2 Extension: mRNA-1010 6.25 ug1/50 (2%)2/50 (4%)45/50 (90%)
Phase 2 Extension: mRNA-1010 12.5 ug0/50 (0%)0/50 (0%)38/50 (76%)
Phase 2 Extension: mRNA-1010 25 ug0/49 (0%)0/49 (0%)45/49 (91.8%)
Most frequent serious events
Showing 10 of 31
Most frequent serious events
EventPhase 1/2: PlaceboPhase 1/2: mRNA-1010 50 ugPhase 1/2: mRNA-1010 100 ugPhase 1/2: mRNA-1010 200 ugPhase 2 NH: Afluria Quadrivalent 60 ugPhase 2 NH: mRNA-1010 25 ugPhase 2 NH: mRNA-1010 50 ugPhase 2 NH: mRNA-1010 100 ugPhase 2 Extension: Afluria Quadrivalent 60 ugPhase 2 Extension: mRNA-1010 6.25 ugPhase 2 Extension: mRNA-1010 12.5 ugPhase 2 Extension: mRNA-1010 25 ug
Post-traumatic amnestic disorderPsychiatric disorders0/450/450/461/440/540/1500/1470/1470/510/500/500/49
Distributive shockVascular disorders0/450/450/461/440/540/1500/1470/1470/510/500/500/49
Pelvic fractureInjury, poisoning and procedural complications0/450/450/461/440/540/1500/1470/1470/510/500/500/49
ConcussionInjury, poisoning and procedural complications0/450/450/461/440/540/1500/1470/1470/510/500/500/49
Kidney contusionInjury, poisoning and procedural complications0/450/450/461/440/540/1500/1470/1470/510/500/500/49
Lumbar vertebral fractureInjury, poisoning and procedural complications0/450/450/461/440/540/1500/1470/1470/510/500/500/49
Rib fractureInjury, poisoning and procedural complications0/450/450/461/440/540/1500/1470/1470/510/500/500/49
Road traffic accidentInjury, poisoning and procedural complications0/450/450/461/440/540/1500/1470/1470/511/500/500/49
Spinal compression fractureInjury, poisoning and procedural complications0/450/450/461/440/540/1500/1470/1470/510/500/500/49
Traumatic liver injuryInjury, poisoning and procedural complications0/450/450/461/440/540/1500/1470/1470/510/500/500/49
Most frequent other events
Showing 10 of 93
Most frequent other events
EventPhase 1/2: PlaceboPhase 1/2: mRNA-1010 50 ugPhase 1/2: mRNA-1010 100 ugPhase 1/2: mRNA-1010 200 ugPhase 2 NH: Afluria Quadrivalent 60 ugPhase 2 NH: mRNA-1010 25 ugPhase 2 NH: mRNA-1010 50 ugPhase 2 NH: mRNA-1010 100 ugPhase 2 Extension: Afluria Quadrivalent 60 ugPhase 2 Extension: mRNA-1010 6.25 ugPhase 2 Extension: mRNA-1010 12.5 ugPhase 2 Extension: mRNA-1010 25 ug
Injection site painGeneral disorders7/4533/4540/4640/4417/54110/150120/147122/14725/5137/5032/5041/49
FatigueGeneral disorders10/4524/4540/4635/4416/5479/15086/14796/14716/5123/5020/5027/49
MyalgiaMusculoskeletal and connective tissue disorders7/4518/4536/4631/4412/5472/15088/14798/14714/5116/5016/5028/49
HeadacheNervous system disorders8/4519/4529/4633/4410/5478/15079/14782/14720/5121/5018/5024/49
ChillsGeneral disorders2/4514/4526/4631/446/5444/15052/14773/1478/519/505/5018/49
ArthralgiaMusculoskeletal and connective tissue disorders3/4510/4528/4627/4411/5457/15068/14773/14710/5112/5013/5025/49
Injection site lymphadenopathyGeneral disorders3/4511/4516/4622/4410/5440/15045/14752/1477/5113/5014/5016/49
VomitingGastrointestinal disorders1/458/4518/4617/445/5423/15031/14730/1473/514/506/5011/49
PyrexiaGeneral disorders0/452/4511/4613/442/5410/15014/14725/1470/510/502/503/49
COVID-19Infections and infestations0/452/452/463/448/5417/15019/14721/1471/515/503/503/49

Baseline characteristics

Safety Set: All randomly assigned participants who received the investigational product.

Age, Continuous
Age, Continuous(years)Phase 1/2: PlaceboPhase 1/2: mRNA-1010 50 ugPhase 1/2: mRNA-1010 100 ugPhase 1/2: mRNA-1010 200 ugPhase 2 NH: Afluria Quadrivalent 60 ugPhase 2 NH: mRNA-1010 25 ugPhase 2 NH: mRNA-1010 50 ugPhase 2 NH: mRNA-1010 100 ugPhase 2 Extension: Afluria Quadrivalent 60 ugPhase 2 Extension: mRNA-1010 6.25 ugPhase 2 Extension: mRNA-1010 12.5 ugPhase 2 Extension: mRNA-1010 25 ugTotal
Mean52.0 (18 to 90)48.2 (18 to 74)52.2 (19 to 83)48.9 (19 to 89)52.4 (20 to 86)50.4 (18 to 86)50.3 (19 to 81)49.9 (18 to 82)40.8 (19 to 65)40.4 (18 to 75)42.8 (19 to 76)38.9 (21 to 74)47.3 (18 to 90)
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1/2: PlaceboPhase 1/2: mRNA-1010 50 ugPhase 1/2: mRNA-1010 100 ugPhase 1/2: mRNA-1010 200 ugPhase 2 NH: Afluria Quadrivalent 60 ugPhase 2 NH: mRNA-1010 25 ugPhase 2 NH: mRNA-1010 50 ugPhase 2 NH: mRNA-1010 100 ugPhase 2 Extension: Afluria Quadrivalent 60 ugPhase 2 Extension: mRNA-1010 6.25 ugPhase 2 Extension: mRNA-1010 12.5 ugPhase 2 Extension: mRNA-1010 25 ugTotal
Female231925333089808624342730500
Male222621112461676127162319378
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase 1/2: PlaceboPhase 1/2: mRNA-1010 50 ugPhase 1/2: mRNA-1010 100 ugPhase 1/2: mRNA-1010 200 ugPhase 2 NH: Afluria Quadrivalent 60 ugPhase 2 NH: mRNA-1010 25 ugPhase 2 NH: mRNA-1010 50 ugPhase 2 NH: mRNA-1010 100 ugPhase 2 Extension: Afluria Quadrivalent 60 ugPhase 2 Extension: mRNA-1010 6.25 ugPhase 2 Extension: mRNA-1010 12.5 ugPhase 2 Extension: mRNA-1010 25 ugTotal
Hispanic or Latino512981227322917121411188
Not Hispanic or Latino393337354212211411434363536677
Unknown or Not Reported10010114021213
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Phase 1/2: PlaceboPhase 1/2: mRNA-1010 50 ugPhase 1/2: mRNA-1010 100 ugPhase 1/2: mRNA-1010 200 ugPhase 2 NH: Afluria Quadrivalent 60 ugPhase 2 NH: mRNA-1010 25 ugPhase 2 NH: mRNA-1010 50 ugPhase 2 NH: mRNA-1010 100 ugPhase 2 Extension: Afluria Quadrivalent 60 ugPhase 2 Extension: mRNA-1010 6.25 ugPhase 2 Extension: mRNA-1010 12.5 ugPhase 2 Extension: mRNA-1010 25 ugTotal
White383841324512412012447443941733
Black or African American5521061718184484101
Asian11100232002012
American Indian or Alaska Native0000012001015
Native Hawaiian or Other Pacific Islander0000011000002
Multiple Race01002311011111
Other Race0010011000014
Race Not Reported10121112000110
Race Unknown0000000000000
08

Study locations

21 sites
  • Cognitive Clinical Trials - Phoenix
    Phoenix, Arizona 85044, United States
  • Alliance for Multispecialty Research, LLC - Phoenix
    Tempe, Arizona 85281, United States
  • Benchmark Research - Colton, CA
    Colton, California 92324, United States
  • Research Centers of America - ERGG - PPDS
    Hollywood, Florida 33024-2709, United States
  • Meridian Clinical Research (Savannah Georgia) - Platinum - PPDS
    Savannah, Georgia 31406, United States
  • Meridian Clinical Research
    Sioux City, Iowa 51106-4233, United States
  • Johnson County Clin-Trials
    Lenexa, Kansas 66219, United States
  • Meridian Clinical Research - Baton Rouge
    Baton Rouge, Louisiana 70809, United States
  • Meridian Clinical Research
    Rockville, Maryland 20854-2957, United States
  • Meridian Clinical Research (Grand Island)
    Grand Island, Nebraska 68803, United States
  • Meridian Clinical Research, LLC (Lincoln Nebraska)
    Lincoln, Nebraska 68510, United States
  • Meridian Clinical Research
    Omaha, Nebraska 68134-3664, United States
  • Meridian Clinical Research (Endwell-New York) - Platinum - PPDS
    Endwell, New York 13760, United States
  • Lucas Research
    Morehead City, North Carolina 28557, United States
  • Trial Management Associates LLC - ERN - PPDS
    Wilmington, North Carolina 28403, United States
  • Meridian Clinical Research - Cincinnati - Platinum - PPDS
    Cincinnati, Ohio 45219, United States
  • Meridian Clinical Research - Cincinnati - Platinum - PPDS
    Cincinnati, Ohio 45246, United States
  • Keystone VitaLink Research - Greenville - PPDS
    Greenville, South Carolina 29615, United States
  • PanAmerican Clinical Research LLC
    Brownsville, Texas 78520, United States
  • Research Your Health - ERN - PPDS
    Plano, Texas 75093, United States
  • South Ogden Family Medicine/Ogden Clinic - CCT
    South Ogden, Utah 84405, United States
09

References and documents

Publications

  • Lee IT, Nachbagauer R, Ensz D, Schwartz H, Carmona L, Schaefers K, Avanesov A, Stadlbauer D, Henry C, Chen R, Huang W, Schrempp DR, Ananworanich J, Paris R. Safety and immunogenicity of a phase 1/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: interim analysis. Nat Commun. 2023 Jun 19;14(1):3631. doi: 10.1038/s41467-023-39376-7. PubMed 37336877 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Sep 2022, 14 months.

Results were first posted in Oct 2023, 1 year 1 month after primary completion.

Of 41 industry-sponsored phase 1/2 interventional studies under Influenza, Human, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's 14 months is close to that.

Counting every sponsor, half of 43 studies reached it within 12 months; a quarter within 7 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2021
First posted
Jul 9, 2021
StartActual
Jul 6, 2021
Primary completionActual
Sep 27, 2022
CompletionActual
Sep 27, 2022
Results first posted
Oct 27, 2023
Last update
Oct 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04956575
Lead sponsor
ModernaTX, Inc.
Responsible party
Sponsor
First posted
Jul 9, 2021
Start date
Jul 6, 2021
Primary completion
Sep 27, 2022
Completion
Sep 27, 2022
Results posted
Oct 27, 2023
Last update
Oct 27, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: mRNA-1010 influenza vaccine

Start the discussion